Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2008

01-12-2008 | Article

Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006–2007

Authors: L. Fenner, R. Frei, M. Gregory, M. Dangel, A. Stranden, A. F. Widmer

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2008

Login to get access

Abstract

A prospective study was conducted during a one-year period between 2006 and 2007 to describe the epidemiology of Clostridium difficile-associated disease (CDAD) at University Hospital Basel, Switzerland (UHBS) and to determine phenotypic and genotypic features of C. difficile strains isolated at the Microbiology Laboratory UHBS including strains from regional non-university hospitals. We prospectively identified 78 CDAD cases at UHBS with an incidence of 2.65/1,000 hospitalised patients or 2.3/10,000 patient-days. Sixteen patients (20.5%) were infected with clindamycin-resistant strains of PCR-ribotype 027 during an outbreak at the geriatric hospital. Among 124 single-patient isolates, 28 (22.6%) were resistant to moxifloxacin and 34 (27.4%) were resistant to clindamycin, but all remained susceptible to metronidazole and vancomycin. Of 102 toxigenic isolates, 19 (18.7%) had an 18-bp deletion in the tcdC gene, eight (7.8%) a 39-bp deletion, and one (1.0%) a 54-bp deletion. Genes for binary toxin were present in 27 (21.8%). PCR-ribotype 027 was associated with older age (median age 83.5 vs. 65.5 years, p < 0.0001) and longer duration of hospitalisation before onset of disease (median 15.5 vs. 9 days, p = 0.014) with a trend towards higher crude mortality, more severe disease, and previous use of macrolides compared to ribotype non-027. Overall, severe disease correlated with use of a nasogastric tube and surprisingly shorter duration of hospitalisation before onset of disease. Today, laboratory-based and epidemiological surveillance systems are required to monitor CDAD cases and emergence of new epidemic strains.
Literature
1.
go back to reference Asha NJ, Tompkins D, Wilcox MH (2006) Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 44:2785–2791. DOI 10.1128/JCM.00165-06 PubMedCrossRef Asha NJ, Tompkins D, Wilcox MH (2006) Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol 44:2785–2791. DOI 10.​1128/​JCM.​00165-06 PubMedCrossRef
2.
go back to reference Guerrant RL, Van GT, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al (2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331–351. DOI 10.1086/318514 PubMedCrossRef Guerrant RL, Van GT, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, et al (2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331–351. DOI 10.​1086/​318514 PubMedCrossRef
3.
go back to reference CDC (2005) Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morb Mortal Wkly Rep 54:1201–1205 CDC (2005) Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morb Mortal Wkly Rep 54:1201–1205
5.
7.
go back to reference Goorhuis A, van der Kooi T, Vaessen N, Dekker FW, van den Berq R, Harmanus C, van den Hof S, Notermans DW, Kuijper EJ (2007) Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 45:695–703. DOI 10.1086/520984 PubMedCrossRef Goorhuis A, van der Kooi T, Vaessen N, Dekker FW, van den Berq R, Harmanus C, van den Hof S, Notermans DW, Kuijper EJ (2007) Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 45:695–703. DOI 10.​1086/​520984 PubMedCrossRef
8.
go back to reference Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44:238–244. DOI 10.1086/510391 PubMedCrossRef Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44:238–244. DOI 10.​1086/​510391 PubMedCrossRef
9.
go back to reference Curry SR, Marsh JW, Muto CA, O’leary MM, Pasculle AW, Harrison LH (2007) tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45:215–221PubMedCrossRef Curry SR, Marsh JW, Muto CA, O’leary MM, Pasculle AW, Harrison LH (2007) tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45:215–221PubMedCrossRef
10.
go back to reference Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, et al (2007) Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000–2004. Infect Control Hosp Epidemiol 28:131–139. DOI 10.1086/511794 PubMedCrossRef Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, et al (2007) Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000–2004. Infect Control Hosp Epidemiol 28:131–139. DOI 10.​1086/​511794 PubMedCrossRef
11.
go back to reference Cohen SH, Tang YJ, Hansen B, Silva J Jr (1998) Isolation of a toxin B-deficient mutant strain of Clostridium difficile in a case of recurrent C. difficile-associated diarrhea. Clin Infect Dis 26:410–412 Cohen SH, Tang YJ, Hansen B, Silva J Jr (1998) Isolation of a toxin B-deficient mutant strain of Clostridium difficile in a case of recurrent C. difficile-associated diarrhea. Clin Infect Dis 26:410–412
12.
go back to reference Van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, et al (2004) Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 42:1035–1041. DOI 10.1128/JCM.42.3.1035-1041.2004 PubMedCrossRef Van den Berg RJ, Claas EC, Oyib DH, Klaassen CH, Dijkshoorn L, Brazier JS, et al (2004) Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol 42:1035–1041. DOI 10.​1128/​JCM.​42.​3.​1035-1041.​2004 PubMedCrossRef
15.
go back to reference Persson S, Torpdahl M, Olsen KEP (2007) Novel multiplex-PCR method for detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied on a Danish cohort. Presented at ECCMID, Nice, France, 2006 Persson S, Torpdahl M, Olsen KEP (2007) Novel multiplex-PCR method for detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied on a Danish cohort. Presented at ECCMID, Nice, France, 2006
17.
go back to reference Stubbs SL, Brazier JS, O'Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463PubMed Stubbs SL, Brazier JS, O'Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463PubMed
18.
go back to reference Clinical and Laboratory Standards Institute (2007) Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard M11-A7, 7th ed. Wayne, PA, USA Clinical and Laboratory Standards Institute (2007) Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard M11-A7, 7th ed. Wayne, PA, USA
20.
go back to reference McCabe WR, Jackson GG (1962) Gram-negative bacteremia. II. Clinical, laboratory and therapeutic observations. Arch Intern Med 127:856–869 McCabe WR, Jackson GG (1962) Gram-negative bacteremia. II. Clinical, laboratory and therapeutic observations. Arch Intern Med 127:856–869
21.
go back to reference Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16:459–477PubMedCrossRef Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16:459–477PubMedCrossRef
22.
go back to reference Archibald LK, Banerjee SN, Jarvis WR (2004) Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 189:1585–1589. DOI 10.1086/383045 PubMedCrossRef Archibald LK, Banerjee SN, Jarvis WR (2004) Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 189:1585–1589. DOI 10.​1086/​383045 PubMedCrossRef
23.
go back to reference Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ (2007) Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 13:1058–1064. DOI 10.1111/j.1469–0691.2007.01793.x Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ (2007) Characteristics and incidence of Clostridium difficile-associated disease in The Netherlands, 2005. Clin Microbiol Infect 13:1058–1064. DOI 10.​1111/​j.​1469–0691.​2007.​01793.​x
24.
go back to reference McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK (2007) Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28:140–145. DOI 10.1086/511798 PubMedCrossRef McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK (2007) Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28:140–145. DOI 10.​1086/​511798 PubMedCrossRef
25.
go back to reference Akerlund T, Svenungsson B, Lagergren A, Burman LG (2006) Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 44:353–358. DOI 10.1128/JCM.44.2.353-358.2006 PubMedCrossRef Akerlund T, Svenungsson B, Lagergren A, Burman LG (2006) Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 44:353–358. DOI 10.​1128/​JCM.​44.​2.​353-358.​2006 PubMedCrossRef
Metadata
Title
Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006–2007
Authors
L. Fenner
R. Frei
M. Gregory
M. Dangel
A. Stranden
A. F. Widmer
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0564-9

Other articles of this Issue 12/2008

European Journal of Clinical Microbiology & Infectious Diseases 12/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.